Credit rating agency, CARE has reaffirmed the assigned ‘A1+’ rating to Commercial Paper (CP) Programme carved out of WC limits of Elder Pharmaceuticals for Rs 105.00 crore. The agency has also reaffirmed the assigned ‘A1+’ rating to Commercial Paper (standalone) Programme of the company for Rs 75.00 crore.
Improvement in the overall capital structure in terms of the reduction in gearing ratios and shortening of the working capital cycle are the key rating sensitivities.
Elder Pharmaceuticals (EPL) is engaged in the manufacturing and marketing of mainly pharmaceutical formulations, under its own as well as in-licensed brands, and offers a gamut of products in the Active Pharmaceutical Ingredients (API)/bulk drugs. The company is also a distributor of the cosmeceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: